Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Authors

Keywords

Journal

Volume -, Issue -, Pages -

Publisher

Oxford University Press (OUP)

Online

2021-08-19

DOI

10.1093/jac/dkab318

References

View 5 related references

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discuss science. Find collaborators. Network.

Join a conversation